Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Lymphoma, T-Cell × Decitabine × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neoplasms 1 Myelodysplastic Syndromes 1 Metastatic Pancreatic Adenocarcinoma 1 Malignant Solid Tumor 1 Lymphoma, T-Cell 1 Lymphoma 1

Interventions

fludarabine 2 Cyclophosphamide 2 pegylated granulocyte colony-stimulating factor, human 1 pegfilgrastim 1 pegaspargase 1 dexamethasone acetate 1 Tetrahydrouridine 1 Surveys and Questionnaires 1 Sugars 1 Melphalan 1 Loratadine 1 Decitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02846935 2019-01-07

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡